Mark Trusheim spoke at on the panel "Collecting & Utilizing Data to Support Gene Therapy Market Access" at the 4th Annual Gene Therapy for Rare Disorders conference representing FoCUS.

On April 12 Mark Trusheim led a workshop for ISPOR, entitled “Adaptive Reimbursement: Innovating for Patient Access and Better Outcomes for All”, including Angela Banks Vice President, External Affairs, UnitedHealth Group; Ron Potts, MD; Medical Director Quality Improvement Kaiser Permanente, Chief Medical Officer, INTERLINK; and David Strutton, PhD, VP, Global Pharmaceuticals & Policy Research, Center for Observational and Real-World Evidence, Merck & Co. Mark recaps the panel in this AJMC update.

Precision therapies are often approved based on small trials, in specialized settings, and using biomarkers as endpoints. Thus, despite their potential high cost, the evidence of value is lacking which makes real-world evidence crucial. Join Schaeffer Center Director of Research Darius Lakdawalla in discussion with MIT NEWDIGS Director of Research Kay Larholt and Merck Center for Observational and Real-World Evidence Executive Director Megan O’Brien for a discussion about how we should measure and leverage real-world data to assess the value…

Mark Trusheim participated in the World Orphan Drug Congress USA 2021 on August 25–27.

Mark Trusheim participated in the ASCGT Policy Forum panel "The Status of Medicaid Coverage and Access for Gene and Cell Therapies" on September 22, and on September 28 he led the roundtable "Preparing for 2022 regulatory change and the performance-based contracting explosion" for the Reuters Cell and Gene Therapy USA meeting. On September 30 Mark spoke in the OHE Master Class Adaptive Pathways: Generating Evidence of Value.